Structure of the homodimeric androgen receptor ligand-binding domain
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
The androgen receptor (AR) plays a crucial role in normal physiology, development and metabolism as well as in the aetiology and treatment of diverse pathologies such as androgen insensitivity syndromes (AIS), male infertility and prostate cancer (PCa). Here we show that dimerization of AR ligand-binding domain (LBD) is induced by receptor agonists but not by antagonists. The 2.15-Å crystal structure of homodimeric, agonist- and coactivator peptide-bound AR-LBD unveils a 1,000-Å 2 large dimerization surface, which harbours over 40 previously unexplained AIS- and PCa-associated point mutations. An AIS mutation in the self-association interface (P767A) disrupts dimer formation in vivo , and has a detrimental effect on the transactivating properties of full-length AR, despite retained hormone-binding capacity. The conservation of essential residues suggests that the unveiled dimerization mechanism might be shared by other nuclear receptors. Our work defines AR-LBD homodimerization as an essential step in the proper functioning of this important transcription factor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A symmetric dimeric AR LBD structure was also solved recently (Nadal et al., 2017), suggesting that AR may form a dimer similar to the way ERα dimerizes.”
From Structural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator Complexes (2020) · cites this paper as Nadal et al., 2017
Experimental — accuracy not yet measuredIn the citing paper
“the Entrenched state is the most compact, exhibiting the best fit for the X-ray structure of a LBD dimer (Nadal et al., 2017), whereas the extended conformation in the Divorced state deviates the most”
From Allosteric interactions prime androgen receptor dimerization and activation (2022) · cites this paper as Nadal et al., 2017
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A method and server for predicting damaging missense mutations.
Adzhubei, I. A., Schmidt, S., Peshkin, L., Ramensky, V. E., Gerasimova, A., Bork, P., Kondrashov, A. S., & Sunyaev, S. R. (2010) · Nature Methods · doi:10.1038/nmeth0410-248 · Cited by 13,194
Molecular basis of agonism and antagonism in the oestrogen receptor
Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M. (1997) · Nature · doi:10.1038/39645 · Cited by 3,355
Nuclear Receptors, RXR, and the Big Bang
Evans, R. M., & Mangelsdorf, D. J. (2014) · Cell · doi:10.1016/j.cell.2014.03.012 · Cited by 1,200
Attard, G., Parker, C., Eeles, R. A., Schröder, F., Tomlins, S. A., Tannock, I., Drake, C. G., & de Bono, J. S. (2016) · The Lancet · doi:10.1016/s0140-6736(14)61947-4 · Cited by 905
Bledsoe, R. K., Montana, V. G., Stanley, T. B., Delves, C. J., Apolito, C. J., McKee, D. D., Consler, T. G., Parks, D. J., Stewart, E. L., Willson, T. M., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00817-6 · Cited by 818
Allostery in Disease and in Drug Discovery
Nussinov, R., & Tsai, C.-J. (2013) · Cell · doi:10.1016/j.cell.2013.03.034 · Cited by 761
Crystallographic comparison of the estrogen and progesterone receptor’s ligand binding domains
Tanenbaum, D. M., Wang, Y., Williams, S. P., & Sigler, P. B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.5998 · Cited by 738
CUPSAT: prediction of protein stability upon point mutations
Parthiban, V., Gromiha, M. M., & Schomburg, D. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl190 · Cited by 695
Atomic structure of progesterone complexed with its receptor
Williams, S. P., & Sigler, P. B. (1998) · Nature · doi:10.1038/30775 · Cited by 659
Structural Evidence for Ligand Specificity in the Binding Domain of the Human Androgen Receptor
Matias, P. M., Donner, P., Coelho, R., Thomaz, M., Peixoto, C., Macedo, S., Otto, N., Joschko, S., Scholz, P., Wegg, A., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004571200 · Cited by 608
Cited by
Items 101–199 of 199
Nguyen, T. T.-N., Nojiri, K., Kurokawa, T., Sawada, T., Kanemoto, Y., & Kato, S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052396 · Cited by 11
“Based on these findings and the SERM [134,136] and selective androgen receptor modulator (SARM) [138] models, it is likely that DLAM-2b induces a different conformation in the VDR than that triggered by 1,25(OH) 2 D 3 [89].”
Jiang, X., Teng, Y., Chen, X., Liang, N., Li, Z., Liang, D., & Wu, L. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.03.036 · Cited by 9
Xie, J., Shen, K., Liang, W., Kuang, Z., Shrestha, R. K., Hanson, A. R., Townley, S. L., He, M., Yu, S., Zhou, P., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2509222122 · Cited by 12
“Structures of the AR - LBD obtained by X - ray crystallography have suggested that disulfide bridges could form between C669–C844 and C844–C852 ( 56 , 57 ), although there is no biochemical evidence supporting these intramolecular interactions.”
McLeod, V. M., Chiam, M. D. F., Perera, N. D., Lau, C. L., Boon, W. C., & Turner, B. J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.808479 · Cited by 10
“org 2 AR protein conformation is stabilised (14), and the complex dimerises (15) and translocates to the nucleus where it binds to androgen response elements on DNA of target genes.”
BackgroundDoamekpor, S. K., Peng, P., Xu, R., Ma, L., Tong, Y., & Tong, L. (2023) · Acta Crystallographica Section F Structural Biology Communications · doi:10.1107/s2053230x23002224 · Cited by 8
Vela‐Rodríguez, C., Yang, C., Alanen, H. I., Eki, R., Abbas, T., Maksimainen, M. M., Glumoff, T., Duman, R., Wagner, A., Paschal, B. M., et al. (2024) · Protein Science · doi:10.1002/pro.4945 · Cited by 8
“Given that AR binds to response element DNA as a homodimer (Nadal et al., 2017; Wasmuth et al., 2022), ADP-ribose reading by the oligomeric DTX3L-PARP9 complex should be an efficient mechanism for concentrating ubiquitin E3 ligase activity on AR target genes.”
BackgroundHage, M. P., Drui, D., Francou, B., Mercier, S., Guiochon‐Mantel, A., Belaisch-Allart, J. C., Péréon, Y., Cazabat, L., de Mazancourt, P., & Raffin‐Sanson, M. L. (2020) · Andrologia · doi:10.1111/and.13865 · Cited by 8
“The 5JJM structure was determined by Nadal et al. (2017).”
Bianchetti, L., Sinar, D., Depenveiller, C., & Dejaegere, A. P. (2021) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26073 · Cited by 10
“In its observed crystallographic position, the F-domain prevents the formation of the canonical dimerization surface through steric hindrance, in agreement with previous reports.(25,27,28,37) The structural statistics also indicate, as could be”
BackgroundResultInfluentialLongoria-García, S., Sanchez-Dominguez, C. N., & Gallardo‐Blanco, H. L. (2022) · Oncology Letters · doi:10.3892/ol.2022.13223 · Cited by 10
“The AR is located in the cytoplasm and, when bound with its ligand, translocates into the cell nucleus recognizing hormone response elements in regulatory genomic regions (11).”
BackgroundZhou, D., Xu, H. Z., Shen, X., Gu, R., Chen, Y., Chen, G., Li, P., Shi, H., Sun, X., & Xin, A. (2022) · Clinica Chimica Acta · doi:10.1016/j.cca.2022.03.021 · Cited by 8
Mechanisms of ligand-mediated modulation of mineralocorticoid receptor signaling
Fuller, P. J., Yang, J., Young, M. J., & Cole, T. J. (2025) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2025.112504 · Cited by 9
Dimerization defective MODY mutations of hepatocyte nuclear factor 4α
Singh, P., Tung, S.-P., Han, E. H., Lee, I., & Chi, Y. (2019) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2019.01.002 · Cited by 7
Dual-function antiandrogen/HDACi hybrids based on enzalutamide and entinostat.
Barrett, R. R., Nash, C., Diennet, M., Cotnoir-White, D., Doyle, C., Mader, S., Thomson, A., & Gleason, J. L. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.128441 · Cited by 4
Xu, S., Kondal, M., Ahmad, A., Zhu, R., Fan, L., Zaborniak, P., Madden, K. S., de Souza, J. V. B., & Bronowska, A. K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021270 · Cited by 8
Helsen, C., Rocca, M. S., Nguyen, T. T., Eerlings, R., Lee, X. Y., Block, S. D., Vinanzi, C., Millo, F. D., Giagulli, V. A., Voet, A. R. D., et al. (2023) · Protein Science · doi:10.1002/pro.4599 · Cited by 6
“The crystal structures of human NR LBDs homodimers, including the AR (PDB ID: 5JJM) (Nadal et al., 2017), GR (PDB: 1M2Z) (Bledsoe et al., 2002), PR (PDB: 1A28) (Williams and Sigler, 1998), ER (PDB:1A52) (Tanenbaum et al., 1998), CAR (PDB: 1XNX) (Shaffer et al., 2004), TRβ (PDB: 3D57) (Jouravel et…”
BackgroundMethodInfluentialSelf-citationGenetic, Environmental, and Nuclear Factors Governing Genomic Rearrangements
Ramanand, S. G., & Mani, R. S. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-32656-2_3 · Cited by 6
Structure-function relationships of the aldosterone receptor
Fuller, P. J., Young, M. J., Yang, J., & Cole, T. J. (2023) · Vitamins and hormones · doi:10.1016/bs.vh.2022.12.007 · Cited by 6
Extra-nuclear and cytoplasmic steroid receptor signalling in hormone dependent cancers
Agbana, S., & McIlroy, M. (2024) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2024.106559 · Cited by 5
“Structural biology data show that the large LBD interaction protein surface potentially harbours up to 40 commonly mutated sites with implication in diseases such as Androgen Insensitivity Syndrome (AIS) through to endocrine resistant prostate cancer [141].”
BackgroundThe androgen receptor amino-terminal domain: structure, function and therapeutic potential
Hunter, I., Jamieson, C., & McEwan, I. J. (2025) · Endocrine Oncology · doi:10.1530/eo-24-0061 · Cited by 10
Chauhan, G., & Heemers, H. V. (2021) · Cancers · doi:10.3390/cancers13163947 · Cited by 7
Chen, C., Chai, X., Hu, X., Lou, S., Li, D., Hou, T., & Cui, S. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00912 · Cited by 6
Interactions governing transcriptional activity of nuclear receptors
Khan, S. H., & Okafor, C. D. (2022) · Biochemical Society Transactions · doi:10.1042/bst20220338 · Cited by 7
Helsen, C., Nguyen, T. T., Vercruysse, T., Wouters, S. M. L., Daelemans, D., Voet, A. R. D., & Claessens, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031557 · Cited by 5
“The structure of the AF2 peptide bound AR LBD; consisting of the AR LBD monomer, DHT and AF2 peptide; was extracted from the AR LBD crystal structure homodimer (PDB: 5jjm) [10].”
BackgroundMethodInfluentialSelf-citationYokobori, K., & Negishi, M. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.11.083 · Cited by 5
Proffitt, M. R., Liu, X., Ortlund, E. A., & Smith, G. T. (2023) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2023.112068 · Cited by 5
Tan, Y., Yuan, S., Huang, H., Tu, C., Du, J., Xu, D., Lin, G., & Lu, G. (2018) · Asian Journal of Andrology · doi:10.4103/aja.aja_32_17 · Cited by 5
Liu, C., Lyu, Y., & Li, P. (2020) · Molecular Genetics and Genomics · doi:10.1007/s00438-020-01686-6 · Cited by 6
“The LBD region is essential for specific hormone-receptor binding, nuclear translocation, protein dimerization, and androgen-induced transcription (Matias and Donner 2000; Centenera and Harris 2008; Nadal and Prekovic 2017).”
BackgroundInfluentialEerlings, R., Barbakadze, N. N., Nguyen, T. T., Nadaraia, N. S., Smeets, E., Moris, L., Handle, F., Kharraz, S. E., Devlies, W., Voet, A. R. D., et al. (2021) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2021.106043 · Cited by 5
Self-citationMészáros, A., Ahmed, J., Russo, G., Tompa, P., & Lázár, T. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1019803 · Cited by 8
“Upon binding androgen hormones by the LBD, AR dissociates from HSPs and undergoes homodimerization through LBD and DBD, and enters the nucleus where it binds specific DNA sequences, called androgen response elements (AREs) (13, 15, 16).”
BackgroundSertad1 promotes prostate cancer progression through binding androgen receptor ligand binding domain
Hu, B., Hu, H., Yin, M., Sun, Z., Chen, X., Li, Y., Sun, Z., Liu, C., Li, L., & Qiu, Y. (2018) · International Journal of Cancer · doi:10.1002/ijc.31877 · Cited by 5
Androgen receptor post-translational modifications and their implications for pathology
Montoya-Novoa, I., Gardeazábal-Torbado, J. L., Alegre‐Martí, A., Fuentes‐Prior, P., & Estébanez‐Perpiñá, E. (2024) · Biochemical Society Transactions · doi:10.1042/bst20231082 · Cited by 4
Self-citationStructural perspectives on the androgen receptor, the elusive shape-shifter
Johnson, M. J., & Wasmuth, E. V. (2024) · Steroids · doi:10.1016/j.steroids.2024.109501 · Cited by 6
Zhao, J., Liu, X., Zhang, T., Luo, H., Zhang, J., & Shao, C. (2025) · Food Bioscience · doi:10.1016/j.fbio.2025.107000 · Cited by 4
Liao, J., Hu, C., Fu, W., Liao, J., Chai, X., Shan, L., Xu, X. N., Hou, T., Sheng, R., & Li, D. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01464 · Cited by 4
Small-molecule disruption of androgen receptor–dependent chromatin clusters
Kohrt, S. E., Novak, E. J., Tapadar, S., Wu, B., Strope, J. D., Asante, Y., Kim, H., Chang, M. S., Gurdak, D., Khalil, A., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2406239121 · Cited by 4
“Leveraging crystal structures of the AR - ligand - binding domain (LBD) ( 30 ), AR dimer structures ( 31 ), and AI - generated models of the AR alpha helix Tau1 ( 32 ), we constructed a homology model of a dimer of AR LBD bound to the AR Tau1 domain ( Fig.”
Takei, T., Hamamura, Y., Hongo, H., Tashiro, E., Imoto, M., Kosaka, T., & Oya, M. (2024) · Cancer Science · doi:10.1111/cas.16349 · Cited by 4
Bhoir, S., & Benedetti, A. D. (2024) · Cancers · doi:10.3390/cancers17010075 · Cited by 3
Falconieri, A., Boarolo, G., Boschelle, C., Spagnolli, G., Marchioretti, C., Zuccaro, E., Palazzolo, I., Tosatto, L., Hegazy, A. K. O., Rosati, J. D., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf688 · Cited by 3
“…degrees of secondary ( α -helix and β -sheet) and tertiary (globular) protein structure, we utilized the crystal structure information available for AR bound to ligand [ 10 , 11 ], and we employed the SWISS-Model to predict whether the DBD-HR-LBD structure is conserved throughout evolution (Fig.”
Iwabuchi, E., Miki, Y., Suzuki, T., & Sasano, H. (2022) · Endocrine Oncology · doi:10.1530/eo-22-0059 · Cited by 4
“AR agonists (testosterone, dihydrotesterone, and R1881) induced intramolecular AR N-terminal domain and AR ligand-binding domain interactions in the nucleus and cytoplasm (Nadal et al. 2017).”
Miyahira, A. K., Hawley, J. E., Adelaiye-Ogala, R. M., Calais, J., Nappi, L., Parikh, R. B., Seibert, T. M., Wasmuth, E. V., Wei, X. X., Pienta, K. J., et al. (2022) · The Prostate · doi:10.1002/pros.24461 · Cited by 6
Paquin, A., Fortin, L., Girouard, J., Reyes‐Moreno, C., Sevrioukova, I. F., & Bérubé, G. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115222 · Cited by 3
García‐Sosa, A. T. (2021) · Molecules · doi:10.3390/molecules26051285 · Cited by 2
Sirokha, D., Gorodna, O., Ложко, Д. М., Livshyts, G. B., Zelinska, N., & Лившиц, Л. А. (2020) · Clinical Case Reports · doi:10.1002/ccr3.3566 · Cited by 3
“11), and dihydrotestosterone 483 pg/mL (24-368).”
Heling, L. W. H. J., van der Veen, J., Rofe, A. P., West, E., Jiménez-Panizo, A., Alegre‐Martí, A., Sheikhhassani, V., Ng, J., Schmidt, T., Estébanez‐Perpiñá, E., et al. (2025) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2025.112634 · Cited by 3
Self-citationAR-targeted therapies sensitize prostate cancer to cuproptosis by transcriptionally activating FDX1
Li, X., Wang, S., Wei, Y., Xie, C., Chen, Y., Wu, F., Zhou, Q., Song, X., Xu, X., Xu, D., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2534978123 · Cited by 4
“AR functions as a nuclear hormone receptor (NHR) that, upon ligand binding, engages chromatin with the assistance of cofactors, including the pioneer factors GATA2 and FOXA1 (2, 3), to activate transcriptional programs supporting tumor growth.”
Thangapandian, S., Idakwo, G., Luttrell, J., Hong, H., Zhang, C., & Gong, P. (2023) · Computational methods in engineering & the sciences · doi:10.1007/978-3-031-20730-3_11 · Cited by 2
Lisberg, A. E., Liu, Y., & Merry, D. E. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107246 · Cited by 2
“These residues are not the only ones that play a role in AR dimerization, as an interaction between the ligand-binding domains of the AR has also been described (27, 28 – 31) and the N/C-interaction itself contributes to dimerized AR structure and function (32 – 34).”
Ahmed, I. M. M., Rofe, A. P., Henry, M. C., West, E., Jamieson, C., McEwan, I. J., & Beveridge, R. (2024) · Protein Science · doi:10.1002/pro.5254 · Cited by 2
Wang, K., Chen, Q., Zhu, Y.-L., & Wang, C. (2021) · World Journal of Clinical Cases · doi:10.12998/wjcc.v9.i35.11036 · Cited by 2
Androgen Receptor Ligands: Agonists and Antagonists
Orafidiya, F. A., Monaghan, A. E., & McEwan, I. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64586-5 · Cited by 2
McEwan, I. J., & Smith, L. B. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64584-1 · Cited by 3
AR homodimerization is essential to function
Fenner, A. (2017) · Nature Reviews Urology · doi:10.1038/nrurol.2017.24 · Cited by 1
Diagnosis and treatment of metastatic prostate cancer
Hu, X., Gallo, R. A., Stoyanova, R. S., Breto, A., Hara, D., Shi, J., Kryvenko, O. N., Abramowitz, M. C., Pra, A. D., Punnen, S., et al. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821789-4.00011-4 · Cited by 1
Cho, H., Jun, I., Adnan, K. M., Park, C. G., Lee, S., Yoon, J., Ryu, C. S., & Kim, Y. J. (2024) · Comparative Biochemistry and Physiology Part C Toxicology & Pharmacology · doi:10.1016/j.cbpc.2024.110048 · Cited by 1
The impact of androgen-induced translation in modulating androgen receptor activity
Israel, J. S., Marcelin, L.-M., Mehralivand, S., Scholze, J., Hofmann, J., Stope, M. B., Puhr, M., Thomas, C., & Erb, H. H. H. (2024) · Biology Direct · doi:10.1186/s13062-024-00550-6 · Cited by 2
“The activated AR then translocates to the nucleus, where the AR-ligand complex dimerises, associates with co-activators, and binds to specific androgen response elements (ARE) on the DNA [1, 3, 9, 10].”
BackgroundThe anabolic steroid stanozolol is a potent inhibitor of human MutT homolog 1
Scaletti, E. R., Westergren, R. G., Almlöf, I., Jemth, A., Scobie, M., Berglund, U. W., Helleday, T., & Stenmark, P. (2025) · FEBS Letters · doi:10.1002/1873-3468.70116 · Cited by 2
“However, it should be noted that dimerization of the AR-LBD is only induced by agonists of the receptor [67].”
The Androgen Receptor: Key to Testosterone Function and Androgen Sensitivity
Paakinaho, V., & Palvimo, J. J. (2025) · Springer eBooks · doi:10.1007/978-3-031-96376-6_12 · Cited by 2
Yang, W., Zhou, J., Li, S., Lai, J., Zhang, M., Zihang, X., Han, C., Li, Q., & Huang, J. (2026) · Comparative Biochemistry and Physiology Part D Genomics and Proteomics · doi:10.1016/j.cbd.2026.101769 · Cited by 1
Cavaliere, F., & Cozzini, P. (2022) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2022.115953 · Cited by 1
Hydropathic AF‐2 variants in the androgen receptor gene among androgen insensitivity patients
Giuliatti, S., Benedetti, A. F. F., Ramos, R. M., Petroli, R. J., Domenice, S., Mendonca, B. B., & Batista, R. L. (2024) · Andrology · doi:10.1111/andr.13680 · Cited by 1
Unveiling the Significance of the Androgen Receptor Gene in Disorders of Sex Development
Maritska, Z., Saleh, M. I., Idris, F., Hafy, Z., Pramudhito, D., & Effendi, K. Y. (2024) · Advances in Human Biology · doi:10.4103/aihb.aihb_137_24 · Cited by 1
Bai, L., Wu, T., Fukasawa, M., Kashiwagi, S., Tate, H., Ozaki, T., Sugano, E., Tomita, H., Ishii, T., Akashi, T., et al. (2024) · Tissue and Cell · doi:10.1016/j.tice.2024.102631 · Cited by 1
Polyglutamine expansion induced dynamic misfolding of androgen receptor
Heling, L. W. H. J., Sheikhhassani, V., Ng, J., van Vliet, M., Jiménez‐Panizo, A., Alegre‐Martí, A., Woodard, J. C., van Roon‐Mom, W., McEwan, I. J., Estébanez‐Perpiñá, E., et al. (2025) · Protein Science · doi:10.1002/pro.70154 · Cited by 1
“This configuration supports the docking and interaction of the previously characterized active LBD dimer (Nadal et al., 2017) in agreement with the crystal structure of the AR-LBD dimer.”
Self-citationYaragani, M., Yadlapalli, P., Raghavan, S. S., Giridhar, T., Mandava, V. B. R., Singh, R. V., Kottapalli, R. P., & Saravanan, C. (2021) · ChemistrySelect · doi:10.1002/slct.202101546 · Cited by 1
Dimerization of the Mineralocorticoid Receptor Ligand Binding Domain by helix 9, 10 and the F-domainPreprint
Bianchetti, L., Sinar, D., Depenveiller, C., & Dejaegere, A. P. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.05.369587 · Cited by 1
Schaper, C. D. (2020) · Preprints.org · doi:10.20944/preprints202009.0300.v1
“As the DNA nucleotides comprising the promoter regions for many genes have been identified, forming a large database [2], the corresponding transcription factors have also been extensively examined [3, 4, 5, 6].”
BackgroundZhou, T.-J., Liu, J., Wang, P., Hu, A.-N., Chen, L., & Zan, J.-F. (2021) · Natural Product Communications · doi:10.1177/1934578x21997677
Androgen Receptors in the Pathology of Disease
Leung, J. K., Tien, A. H., & Sadar, M. D. (2021) · Springer eBooks · doi:10.1007/978-3-030-78315-0_16 · Cited by 1
Modulation of the Androgen Receptor Axis
Mohler, M. L., & Dalton, J. T. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc055.pub2
McEwan, I. J. (2018) · Wiley eBooks · doi:10.1002/9780470015902.a0006090.pub3
Ahmed, J., Claridge, J. K., Mészáros, A., & Tompa, P. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.04.551977
Kumari, N., Kashyap, J., & Tyagi, R. K. (2023) · Journal of Endocrinology & Reproduction · doi:10.18311/jer/2023/34987
Antiprostate cancer oncological drugs
Albuquerque, E. L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15530-7.00004-x
Expansão do diagnóstico molecular da Síndrome de Insensibilidade aos Andrógenos
Ramos, R. M. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.5.2023.tde-12042024-144254
The Importance of Andrographolide and its Analogs in Prostate Cancer
Kotha, K. K., Lolla, S., Deepa, M., Papichettypalle, G., Mani, R. R., Palei, N. N., Dhar, A. K., Keshri, P. K., Muthumanickam, A., Nuli, M. V., et al. (2024) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815256567124010011
Structural characterization of complexes of Intrinsically Disordered Proteins
Mészáros, A. (2024) · Eötvös Loránd Tudományegyetem · doi:10.15476/elte.2024.142
Androgen Receptor Ligands: Agonists and Antagonists
Orafidiya, F. A., Monaghan, A. E., & McEwan, I. J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-21477-6.00453-3
McEwan, I. J., O’Donnell, L., & Smith, L. B. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-21477-6.00452-1
Ali, A., Pastena, F. D., Biziotis, O., Wang, S., Tsakiridis, E. E., Rosso, D. D., Fredenburgh, J. C., Weitz, J. I., Hotte, S. J., Bramson, J. L., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218535
Jin, J., Huang, F., Chen, Q., Yu, H., Tan, H., & Shi, W. F. (2025) · Environmental Science & Technology Letters · doi:10.1021/acs.estlett.5c01043
Yamazaki, S., & Reddy, A. B. (2026) · iScience · doi:10.1016/j.isci.2026.117289 · Cited by 1
Bianchetti, L. (2019) · theses.fr (ABES) · doi:10.70675/8c0410e5zb455z44d6z8522z8cbe8649e112
Liao, B., Shuai, M., Xiao, L., Huang, G., He, Y., Wang, Y., Wang, H., & He, S. (2026) · BMC Medical Genomics · doi:10.1186/s12920-026-02374-x
“Functionally, LBD is essential for high-affinity binding of dihydrotestosterone (DHT) and proper nuclear translocation of the AR, which are critical steps for transcriptional activation of androgen-responsive genes [28, 29].”
Role of Underutilized Plant-Derived Metal Oxide-Based Nanoparticles Against Prostate Cancer
Bhardwaj, N., Bhardwaj, I., Dulta, K., Nepovimová, E., Kuča, K., Choudhary, M., Mandyal, P., Choudhary, A., & Peter, L. (2026) · Springer eBooks · doi:10.1007/978-3-032-20384-7_10
Chai, X., Hou, T., & Li, D. (2026) · Accounts of Chemical Research · doi:10.1021/acs.accounts.6c00261
Mechanisms of resistance to androgen deprivation therapy in prostate cancer
Bensalim, I., Belyamani, L., Boutayeb, S., & Bourais, I. (2026) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2026.101488 · Cited by 1
Mondal, I., Gorai, A., Mandal, S. K., Samanta, S. K., Halder, A. K., & Ojha, P. K. (2026) · ChemistrySelect · doi:10.1002/slct.74087
Regulation of the Mineralocorticoid Receptor in Physiology and Disease
Young, M. J., Fuller, P. J., Meijer, O. C., Cole, T. J., Kanki, M., Yang, J., Ho, Q. V., Karthigan, N., & Heanue, S. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100156
Release of bound steroid from the androgen and estrogen receptors is induced by DDT and its analogs
Rosales, M. D., Soto, T., Goodship, J., Cruz, A. R., Rodriguez, I. A., Flores, V. C., Chavez, A., Solis, M. P., Lopez, E., Dean, F. B., et al. (2026) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2026.118015
Singhera, F. U., Overhulse, J. M., Lee, T. M., Katz, J. G., Lee, J. S. H., & McKenna, C. E. (2026) · Cancers · doi:10.3390/cancers18182939
Mao, D., Fan, L., Zhang, Y., & Gong, C. (2026) · Human Mutation · doi:10.1155/humu/1882678
“Variants impair AR structure or function, rendering target tissues insensitive to androgens critical for virilization [4, 5].”
BindingDB Entry 50016950: Therapeutic Strategies to Target the Androgen Receptor.
BindingDB (2023) · UC San Diego · doi:10.7270/q2j1076h
BindingDB Entry 50014507: Innovative C
BindingDB (2022) · UC San Diego · doi:10.7270/q2s1869n
BindingDB (2023) · UC San Diego · doi:10.7270/q2cz3c62
BindingDB Entry 50015824: Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1
BindingDB (2023) · UC San Diego · doi:10.7270/q2n58rc9
Metadata
- Authors
- Nadal, M., Prekovic, S., Gallastegui, N., Helsen, C., Abella, M., Zielinska, K., Gay, M., Vilaseca, M., Taulès, M., Houtsmuller, A. B., van Royen, M. E., Claessens, F., Fuentes-Prior, P., & Estébanez-Perpiñá, E.
- Affiliations
- Agència de Gestió d'Ajuts Universitaris i de Recerca (ES)
- KU Leuven (BE)
- Institute for Research in Biomedicine (ES)
- Erasmus MC (NL)
- ORCID
- Venue
- Nature Communications
- Published
- 2017-02-06
- Volume
- 8
- Issue
- 1
- Pages
- 14388-14388
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC5303882
- OpenAlex
- W2586987557
- Cited by
- 193
- References
- 59
- Citations by year
- 2026: 16 · 2025: 15 · 2024: 30 · 2023: 21 · 2022: 22 · 2021: 32 · 2020: 21 · 2019: 13 · 2018: 17 · 2017: 5
- FWCI
- 12.67
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RECERCAT (Consorci de Serveis Universitaris de Catalunya) (publishedVersion, other-oa)
- Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by)
- Lirias (submittedVersion, cc-by)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, cc-by)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- RePub (Erasmus University Rotterdam) (submittedVersion)
- Funders
- Generalitat de Catalunya
- Fonds Wetenschappelijk Onderzoek (G068412N, GOA/15/017, G083013N)
- KU Leuven (GOA/15/017)
- Kom op tegen Kanker
- Vlaamse regering
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- androgen receptor, ligand-binding domain, homodimerization, crystal structure, coactivator peptide, androgen insensitivity syndrome, prostate cancer, point mutations, transcriptional activation, nuclear receptors, transcription factors
- MeSH terms
- Protein Domains, Androgens, Animals, Chlorocebus aethiops, Humans, Ligands, Male, Models, Molecular, Prostatic Neoplasms, Receptors, Androgen, Androgen-Insensitivity Syndrome, Point Mutation, Crystallography, X-Ray, COS Cells, Surface Plasmon Resonance, Protein Structure, Quaternary, Ubiquitin-Activating Enzymes, Cell Line, Tumor, Protein Multimerization, Androgen Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.